Zoetis (ZTS)
(Delayed Data from NYSE)
$179.66 USD
+0.28 (0.16%)
Updated Jul 24, 2024 04:00 PM ET
Pre-Market: $179.66 0.00 (0.00%) 9:24 AM ET
4-Sell of 5 4
D Value A Growth A Momentum B VGM
Zoetis (ZTS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$213.75 | $248.00 | $180.00 | 18.97% |
Price Target
Based on short-term price targets offered by 12 analysts, the average price target for Zoetis comes to $213.75. The forecasts range from a low of $180.00 to a high of $248.00. The average price target represents an increase of 18.97% from the last closing price of $179.66.
Analyst Price Targets (12)
Broker Rating
Zoetis currently has an average brokerage recommendation (ABR) of 1.04 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 1.04 a month ago based on 14 recommendations.
Of the 14 recommendations deriving the current ABR, 13 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 92.86% and 7.14% of all recommendations. A month ago, Strong Buy made up 92.86%, while Buy represented 7.14%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ZTS.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 13 | 13 | 13 | 13 | 13 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/22/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/27/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/6/2024 | Goldman Sachs | Nathan Rich | Strong Buy | Strong Buy |
5/3/2024 | Atlantic Equities | Steven K Chesney | Strong Buy | Strong Buy |
4/23/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/16/2024 | Piper Sandler | David M Westenberg | Strong Buy | Strong Buy |
4/12/2024 | William Blair | Brandon Vazquez | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Steve M Scala | Strong Buy | Strong Buy |
12/19/2023 | Not Identified | Not Identified | Strong Buy | Strong Buy |
12/7/2023 | Exane BNP Paribas | Navann Ty | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.04 |
ABR (Last week) | 1.04 |
# of Recs in ABR | 14 |
Average Target Price | $213.75 |
LT Growth Rate | 11.20% |
Industry | Medical - Drugs |
Industry Rank by ABR | 103 of 252 |
Current Quarter EPS Est: | 1.49 |